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Structural changes contribute to airway hyperresponsiveness and airflow obstruction in asthma. Emerging evidence points to the
involvement of c-kit+ cells in lung homeostasis, although their potential role in asthma is unknown. Our aim was to isolate c-kit+
cells from normal mouse lungs and to test whether these cells can interfere with hallmarks of asthma in an animal model. Adult
mouse GFP-tagged c-kit+ cells, intratracheally delivered in the ovalbumin-induced airway hyperresponsiveness, positively affected
airway remodeling and improved airway function. In bronchoalveolar lavage fluid of cell-treated animals, a reduction in the number
of inflammatory cells and in IL-4, IL-5, and IL-13 release, along with an increase of IL-10, was observed. In MSC-treated mice, the
macrophage polarization to M2-like subset may explain, at least in part, the increment in the level of anti-inflammatory cytokine
IL-10. After in vitro stimulation of c-kit+ cells with proinflammatory cytokines, the indoleamine 2,3-dioxygenase and TGF𝛽 were
upregulated.These data, together with the increased apoptosis of inflammatory cells in vivo, indicate that c-kit+ cells downregulate
immune response in asthma by influencing local environment, possibly by cell-to-cell contact combined to paracrine action. In
conclusion, intratracheally administered c-kit+ cells reduce inflammation, positively modulate airway remodeling, and improve
function. These data document previously unrecognized properties of c-kit+ cells, able to impede pathophysiological features of
experimental airway hyperresponsiveness.
1. Introduction
Asthma is a chronic inflammatory disorder of the airways
characterized by variable airway hyperresponsiveness (AHR)
and obstruction. It is estimated that about 300 million people
worldwide suffer from asthma and that globally asthma
accounts for about one in every 250 deaths [1–3]. The
establishment of chronic inflammation is at the basis of
mucus overproduction and airway remodeling that result
in bronchial hyperactivity and variable degree of airflow
obstruction [4–6]. In this regard, the release of several
growth factors and the activation of local progenitor cells
are important aspects to control inflammation and airway
remodeling thus preventing asthma exacerbation [7, 8].
Regionally distinct resident cells with stem/progenitor
characteristics include basal cells and their side population
[9, 10], Clara cells and their variants [11], bronchoalveolar
stem cells [12], alveolar epithelial type II progenitor cells
[13, 14], lung-derived mesenchymal stem cells (MSCs) [15],
and c-kit+ stem cells [16–19].
The importance of c-kit+ cells in lung homeostasis has
been emphasized by the observations that c-kit mutant mice
show abnormal lung architecture and that the expansion
of epithelial progenitors depends on c-kit activation [20].
The contribution of c-kit receptor (also known as CD117
or stem cell factor receptor) during lung development has
been demonstrated in newborn genetically modified mice
whose lungs show a massive contribution of c-kit+ cells [21].
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Furthermore, c-kit receptor has been detected on CD133+
epithelial progenitor cells [22] and in endothelial cells of
alveolar capillaries [23]. A recent paper has tested the lineage
potential of c-kit+ cells, evidencing their direct contribution
to the vascular endothelial cell fate [17], whereas another
study conducted on human fetal and postnatal lungs has
claimed that c-kit expression marks a progenitor popula-
tion restricted to endothelial lineage, suggesting a potential
involvement of c-kit signaling in lung vascular development
[18]. Finally, in an experimental model of lung emphysema,
c-kit-expressing cells mitigate the progression of the disease
upon being activated by hepatocyte growth factor [24].
Although the presence of c-kit+ cells in the lung has been
repeatedly reported, suggesting that this receptor (and its
endogenous ligand)may have clinical significance, properties
of c-kit-bearing cells have not been completely elucidated.
Therefore, the objective of this study was to test which role
c-kit+ cells, isolated from normal mouse lungs, may play in
inflammatory processes and airway remodeling that underlie
pathophysiology of AHR in an animal model.
2. Methods
2.1. Cell Isolation and Culture. Six/eight lungs were harvested
from 2-3-month-old BALB/c male mice (Harlan Laborato-
ries, San Pietro al Natisone, Italy) for each isolation ofmurine
lung c-kit+ cells and fibroblasts. Samples were collected in
100mm diameter culture dishes and were quickly washed
with DPBS w/o Ca2+ and Mg2+ (Euroclone, Milan, Italy) to
wash out blood. Large vascular and bronchial components
were removed as well. In order to obtain a cell suspen-
sion, lungs were tiny minced and enzymatically dissociated
with a prewarmed collagenase solution [280U/mL type II
collagenase (Worthington, Lakewood, NJ, USA); 100U/mL
penicillin and 100mg/mL streptomycin (pen/strep, Euro-
clone)]. After a 45min digestion at 37∘C under agitation,
collagenase was inactivated by adding a double volume of
precooled quenching buffer [0.5% bovine serum albumin
(Sigma-Aldrich, St. Louis, MO, USA); pen/strep]. Cell sus-
pension was further purified by several passages through
cell strainers [70 and 40𝜇m pores (BD Biosciences, Franklin
Lakes, NJ, USA)] and centrifuged at 1200 rpm for 10min to
remove debris. Cell pellet was collected and then washed
with DPBS. After centrifugation (1200 rpm for 10min), cell
pellet was plated in 60mmdiameter culture dishes. Cells were
cultured in Ham’s F12 medium (Euroclone), supplemented
with 10% (v/v) fetal bovine serum (Thermo Fisher Scientific,
Waltham, MA, USA), 5% (v/v) horse serum (Peprotech,
Rocky Hill, NJ, USA), 100mM glutathione (Sigma-Aldrich),
10U/mL erythropoietin (Sigma-Aldrich), 100𝜇g/mL bFGF
(Peprotech), and pen/strep. Twenty-four hours later, floating
cells were removed and adherent cells, mainly composed of
fibroblasts, were cultured under the same conditions. Super-
natant was saved, centrifuged (1200 rpm for 10min), and
plated separately. Supernatant cell cultures were expanded
until P2 to undergo immunomagnetic cell sorting in order
to obtain c-kit+ cells. Specifically, mouse CD117 microbeads
were employed according to manufacturer’s instructions
(Miltenyi Biotec, Gladbach, Germany). At P2-P3, cells were
characterized by FACS and immunolabeling to assess cell
phenotype.
2.2. FACS Analysis. Total isolated cells extracted from lung
tissue were analyzed by FACS (FACScalibur, BD Biosciences)
for the detection of a c-kit+ subpopulation (BD Biosciences,
Italy). After magnetic sorting, c-kit-enriched cells were ana-
lyzed for hematopoietic lineage marker by using CD45 anti-
body (BD Biosciences). Isotype-matched negative controls
were utilized to define the threshold for each specific signal
and to establish the appropriate gating. Data were analyzed
with the instrument software.
2.3. In Vitro Stimulation of c-kit+ Cells. 1.5 × 105 c-kit+ cells
were simultaneously stimulated with 10 ng/mL TNF𝛼 and
10 ng/mL IFN𝛾 (Merck Millipore, Darmstadt, Germany)
to mimic inflammatory environment [25]. Total RNA was
extracted after 3, 6, 12, and 24 h. IFN𝛾 and TNF𝛼, commonly
used cytokines for in vitro cell priming, induce secretion
of molecules involved in the regulation of tissue home-
ostasis, including indoleamine 2,3-dioxygenase (IDO) and
prostaglandin E2 [26].
2.4. Quantitative RT-PCR. Total RNA was extracted with
TRIzol from rested and primed c-kit+ cells for the detection
of IDO, transforming growth factor 𝛽 (TGF𝛽), and IL-10
transcripts (KiCqStart SYBRGreen Primers; Sigma-Aldrich).
HPRT was used as housekeeping gene. iScript One-Step RT-
PCR Kit with SYBR Green (Bio-Rad Laboratories, Milan,
Italy) was employed to perform quantitative RT-PCR and
3 ng of total mRNA from any sample was used as template.
Cycling conditions were performed according to manufac-
turer’s instructions: cDNA synthesis (10min at 50∘C); reverse
transcriptase inactivation (5min at 95∘C); PCR cycling and
detection (42 cycles; 10 sec at 95∘C; 30 sec at 58∘C); melt
curve analysis (1min at 95∘C, 1min at 55∘C, 5 sec at 55–95∘C,
increasing by 0.5∘C each cycle). A CFX96 Real-Time PCR
Detection System was employed (Bio-Rad Laboratories).
2.5. Immunocytochemistry. For immunolabeling, c-kit+ cells
were fixed in 4% paraformaldehyde and incubated with
anti-CD117 (Santa Cruz Biotechnology, Dallas, TX, USA).
Omission of the primary antibody was used as a negative
control.
2.6. GFP Lentiviral Infection. After in vitro expansion, c-kit+
cells were infected with Cignal Lentivirus carrying GFP and
puromycin resistance genes at a MOI of 50 (Qiagen, Milan,
Italy). After 24 h, cells were washed and infection medium
was replaced by fresh medium. At this time, Cignal reporter
constructs were integrated into the genomic DNA. To select
the cells stably expressing the reporter GFP gene, puromycin
(5 𝜇g/mL) selection was performed. GFP+ c-kit+ cells were
collected by centrifugation and diluted at the density of 5 ×
104 cells/50 𝜇L in the appropriatemediumandused for in vivo
procedures.
2.7. Experimental Protocol. To induce asthma, BALB/c mice
(Harlan Laboratories) at 6 weeks of age were sensitized by
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s.c. injections of 0.4mL of 10 𝜇g OVA, absorbed to 3.3mg
of aluminum hydroxide gel in sterile saline at days 0 and
7. From day 21, mice were challenged with nebulized OVA
(1% in PBS) for 7min, three days per week for three weeks
by an ultrasonic nebulizer (De Vilbiss Health Care, Tipton,
UK). OVA derived from chicken egg is a frequently used
allergen that induces an allergic pulmonary inflammation
in laboratory rodents [27, 28]. Mice were randomized into
three experimental groups: (1) control group (𝑛 = 13),
not subjected to any sensitization and treatment; (2) OVA
group (𝑛 = 16), sensitized and challenged with OVA and
injected with medium; (3) OVA+c-kit+ cells (OVA+cCs)
group (𝑛 = 20), sensitized and challenged with OVA and
treated with c-kit+ cells (5 × 104 cells/50 𝜇L medium). Either
medium or c-kit+ cells were intratracheally administered on
day 31, 24 h after the second week of OVA challenge. All
mice were sacrificed 10 days later and lung reactivity test or
bronchoalveolar lavage (BAL) was performed. Separate sets
of animals were used for lung reactivity assay or BAL collec-
tion to avoid the possibility that BAL procedure could affect
lung reactivity measurements. After the assessment of lung
reactivity, lungs were perfused and fixedwith 10% phosphate-
buffered formalin for histology. A schematic representation
of the experimental protocol is displayed in Figure 2(a).
Additional animals (𝑛 = 5) were given lung fibroblasts (5 ×
104 cells/50 𝜇Lmedium) to perform a comparative analysis of
lung function.
2.8. Intratracheal Cell Administration. Prior to cell admin-
istration, mice were anesthetized with ketamine HCl
(40mg/kg, i.p.) and medetomidine HCl (0.15mg/kg, i.p.).
A 20-gauge custom-made catheter was inserted into the
trachea via the mouth and connected to a mouse ventilator
(Harvard Apparatus, Holliston, MA, USA). After confirming
the correct position of the catheter in the trachea and
disconnecting the ventilator, c-kit+ cells or lung fibroblasts
were delivered through the catheter using a syringe with a
fine needle. Afterward, mice were mechanically ventilated
for 3min and then placed in a warm chamber until they
recovered consciousness, usually within 5–15min. Mice from
the OVA group received equal volume of medium.
2.9. Lung Reactivity Assay. Lung reactivity was assessed in
isolated and perfused mouse lung model. As previously
described, water-jacketed perspex chamber (water temper-
ature, 37∘C) was used to accommodate surgery, perfusion,
and ventilation [29]. In anesthetized mouse, the trachea
was exposed and cannulated. The abdomen was opened, the
diaphragm was cut, and 50 𝜇L of heparin were injected into
the heart. The mouse was exsanguinated after the incision
of the renal vein, the thorax was opened, and the two
thoracic halves were fixed with two cannulae at sides on
the cork plate. Afterward, pulmonary artery was cannulated
through and fixed by the ligature. Increased concentrations of
acetylcholine (ACh) were administered through the arterial
cannula into the pulmonary artery. The lungs were perfused
in a nonrecirculating fashion through the pulmonary artery
at a constant flowof 1mL/min resulting in a pulmonary artery
pressure of 2-3 cmH2O. As a perfusion medium, RPMI 1640
lacking phenol red (37∘C) that contained 4% low endotoxin
grade albumin was used. The lungs were ventilated by
negative pressure (−3 to−9 cmH2O)with 90 breaths/min and
a tidal volume of about 200𝜇L. Every 5min a hyperinflation
(−20 cmH2O) was performed. Artificial thorax chamber
pressure wasmeasuredwith a differential pressure transducer
(Validyne DP 45–24, Validyne Engineering, Northridge,
CA, USA), and airflow velocity with a pneumotachograph
tube connected to the differential pressure transducer. The
lungs respired humidified air. The arterial pressure was
continuously monitored with a pressure transducer (Isotec;
Healthdyne Cardiovascular, Costa Mesa, CA, USA) which
was connected with the cannula ending in the pulmonary
artery. All data were transmitted to a computer and analyzed
by the Pulmodyn software (Harvard Apparatus). For lung
mechanics, the data were analyzed by applying the following
formula: 𝑃 = 𝑉 ⋅ 𝐶 − 1 + 𝑅𝐿 ⋅ 𝑑𝑉 ⋅ 𝑑𝑡 − 1, where 𝑃 is chamber
pressure, 𝐶 pulmonary compliance, 𝑉 tidal volume, and 𝑅𝐿
airway resistance. After 60min, the mean tidal volume, mean
airway resistance, and mean pulmonary artery pressure were
stabilized at the baseline. The measured airway resistance
was corrected for the resistance of the pneumotachometer
and the tracheal cannula of 0.6 cmH2Os/mL. Successively, a
repetitive dose-response curve to ACh (10−8 to 10−3M) in all
experimental groups was obtained.
2.10. Bronchoalveolar Lavage. BAL was collected as follows:
0.5mL of saline was instilled and withdrawn from the lungs
via an intratracheal cannula. Lavagewas repeated three times,
and different samples were collected. BAL was centrifuged
at 1000𝑔 for 10min at 4∘C. The supernatant was transferred
into tubes and stored at −70∘C for cytokine analysis. Cell
pellets were resuspended in phosphate-buffered saline to a
final volume of 0.5mL for total and differential cell count.
2.11. Total and Differential Cell Count. Total cell count
was performed with the Countess automated cell counter
(Thermo Fisher Scientific) which evaluates cell count and
viability using trypan blue stain according to the manu-
facturer’s instructions. Differential counting was performed
by Reastain Diff-Quik kit (Thermo Fisher Scientific) and at
least 300 cells were counted on each cytospin according to
standard morphologic criteria under light microscopy.
2.12. Cytokine Assay. Measurement of cytokines in the BAL
was performed taking advantage of a well-established
method, Luminex xMAP technology, that allows measuring
a panel of multiple analytes on a small volume sample
(100 𝜇L) simultaneously [30]. The assay, for the quantitative
detection of IL-4, IL-5, IL-10, and IL-13, was performed
using a Milliplex Cytokine Panel plate (Merck Millipore)
according to the manufacturer’s instructions on automated
immunoassay analyzer (Luminex 200 System, Thermo
Fisher Scientific) as previously described [31]. All samples
were run in duplicate. After the run, data were analyzed by
using Xponent software (1.9 version, Luminex 200 System;
Thermo Fisher Scientific) and the final concentration of each
cytokine was expressed in pg/mL.
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2.13. Histochemistry and Immunofluorescence. Tissue sec-
tions, 5 𝜇m in thickness, were used for histology. By
immunofluorescence, injected cells were detected by GFP
antibody (Abcam, Cambridge, UK) [32]. Cycling epithelial
and smooth muscle cells (SMCs) were identified by Ki67
labeling (Vector Laboratories, Burlingame, CA, USA). The
mucous cell metaplasia was assessed by the immunolabeling
with anti-mucin 5ACantibody (Abcam).Mucin-positive cells
were quantified in the epithelial layer of the bronchi by
counting labeled cells per total number of cells within the
airway epithelium. Inflammatory cells were recognized by
CD45 expression (Novus Biologicals, Littleton, CO, USA).
Macrophages were identified by pan-macrophage marker
F4/80 (Novus Biologicals) and M1/M2 subsets by inducible
nitric oxide synthase (iNOS, Thermo Fisher Scientific)
and arginase-1 expression (Abcam), respectively. Terminal
deoxynucleotidyltransferase-mediated dUTP nick end label-
ing (TUNEL) assay was used for the detection of apoptosis
in the lung tissue, according to manufacturer’s instruc-
tions (Clontech Laboratories, Mountain View, CA, USA).
Apoptotic index was expressed as the number of TUNEL+
cells per million of cells within inflammatory infiltrate.
Nuclei were stained with DAPI (Sigma-Aldrich). Fluorescein
isothiocyanate (FITC) and tetramethylrhodamine-5-(and 6)-
isothiocyanate (TRITC) conjugated secondary antibodies
were used (Jackson ImmunoResearch, Newmarket, UK).
For the assessment of inflammation, tissue sections were
stained with H&E (Sigma-Aldrich). The number of mast
cells per mm2 of the lung tissue was measured after staining
with toluidine blue (Sigma-Aldrich) [33]. Sample area was
measured with Image Pro Plus software (Media Cybernetics,
Rockville, MD, USA). Samples were analyzed with Leica DM
5000B microscope (Leica Microsystems, Wetzlar, Germany)
and Zeiss LSM 700 confocal microscope (Zeiss, Oberkochen,
Germany).
2.14. PCR for Detection of GFP DNA. For PCR detection
of GFP, paraffin sections were obtained from the lungs
of mice in which GFP+ cells were previously detected by
immunohistochemistry. Tissue sections were deparaffinized
and 100 ng genomic DNA, extracted with the QIAamp DNA
kit (Qiagen), were mixed with GFP primers. Cycling condi-
tions were as follows: 94∘C for 30 sec, followed by 30 cycles
of amplification (94∘C for 30 sec, 62∘C for 30 sec, and 72∘C
for 30 sec), with a final incubation at 72∘C for 3min. PCR
products were run onto agarose gel for the detection of the
GFP band (amplicon size: 315 bp). DNA extracted from GFP
rats was used as positive control while tissue sections from
medium-injected mice were used as negative control [34].
2.15. Statistical Analysis. Results were reported as mean ±
SD. Data were analyzed by using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). Significance between two
comparisons was determined by Student’s t-test and among
multiple comparisons by one-way ANOVA and Bonferroni’s
posttest. Lung reactivity curves were compared using a two-
way ANOVA followed by Bonferroni’s posttest. A value of
𝑃 < 0.05 was considered as significant.
2.16. Animal Studies Approval. The experimental protocol
was approved by the Animal Care and Use Committee of
the Second University of Naples (1966/7.17.2012). Animal
care complied with Italian regulations on protection of
animals used for experimental and other scientific purposes
(116/1992) as well as with the EU guidelines for the use of
experimental animals (2010/63/EU).Mice were housed in the
Animal Facility of the Second University of Naples. Food
and water were supplied ad libitum. Room temperature was
kept at 22∘C–24∘C and relative humidity at 40%–50%. The
day/night cycle was set at 12 h/12 h. Mice were acclimatized
for one week before starting any procedures and, during this
time, they were submitted to a daily handling to get them
used to manipulation, thus reducing experimental variability
due to the stress due to the procedures. All treatments were
performed by experienced operators and in asepsis. During
challenge (aerosol), freelymovingmicewere kept in a suitable
chamber with theminimal stress. No animal became severely
ill or died during the in vivo procedures. Mice subjected to
lung reactivity were exsanguinated after incision of the renal
vein, while the remaining animals were sacrificed by cervical
dislocation.
3. Results
3.1. Identification and Isolation of c-kit+ Cells. c-kit+ cells were
detected in adultmouse lung tissue (Figure 1(a)).They did not
express CD45, excluding hematopoietic lineage (Figure 1(b)),
and were negative for characteristic epithelial markers, such
as pan-cytokeratin, thyroid transcription factor 1, and cystic
fibrosis transmembrane conductance regulator as well as
mast cell tryptase (not shown). FACS analysis showed a small
fraction of c-kit+ cells in physically separated small lung cells
obtained by tissue enzymatic digestion (Figure 1(c)). After-
ward, immunosorting yielded c-kit-enriched cell population
that was negative CD45 (Figures 1(d) and 1(e)).
3.2. Airway Hyperresponsiveness and Engraftment of c-kit+
Cells. c-kit+ cells were intratracheally instilled in experimen-
tal animals inwhich airway hyperresponsivenesswas induced
by sensitization and challenge with OVA (Figure 2(a)). Prior
to administration, the cells were transducedwithGFP to trace
them within the recipient tissue (Figure 2(b)). In OVA mice,
ACh-induced bronchoconstriction increased with respect to
controls, while a significant reduction in bronchial hyperre-
activity was observed in the animals that received c-kit+ cells.
Lung fibroblasts did not produce a significant beneficial effect
(Figure 2(c)). This comparative analysis using an additional
cell type (i.e., lung fibroblasts) was done to elucidate whether
the modulation of lung function was dependent on the cell
class. The presence of GFP+ cells in the recipient tissue was
evidenced by PCR for GFP gene and immunohistochemistry
that showed GFP-tagged cells at the level of bronchial
epithelium and lung parenchyma (Figures 2(d)–2(f)).
3.3. Airway Remodeling. Proliferating epithelial and SMCs
were detected in the airways documenting the contribution
of hyperplasia to the airway remodeling. In OVA mice, the
fraction of Ki67+ epithelial and SMCs was nearly 6-fold and




















































Figure 1: In situ detection, isolation, and characterization of c-kit+ cells. (a) c-kit+ cells (green, inset) in a normal adult mouse lung. (b) An
example of c-kit+ cell (green, arrow) and CD45+ cell (red, arrowhead). (c) FACS scatter plots showing the expression of c-kit in a population
of small lung cells. (d) Expression of c-kit (green) on sorted cells shown by immunocytochemistry. (e) FACS analysis of c-kit sorted cells
showing lack of expression of hematopoietic lineage marker CD45. Scale bars, (a) 50𝜇m, (b) 5 𝜇m, and (d) 20 𝜇m.


















































Figure 2: In vivo engraftment of GFP-labeled c-kit+ cells and pulmonary function. (a) Scheme of in vivo experiments. (b) Efficiency of
GFP transfection. Phase contrast and GFP fluorescence image of living c-kit+ cells after lentiviral transduction. (c) Airway reactivity to
acetylcholine (ACh, in moles) as change in resistance (RL) in control, asthmatic (OVA), c-kit+ cell-treated (OVA+cCs), and fibroblast-treated
(OVA+Fibroblasts) mice. (d) Detection of GFP gene by PCR in the lungs of vehicle- and c-kit+ cell-treated mice. (e, f) Engraftment of GFP-
labeled cells after intratracheal administration. Scale bars, (e, f) 20 𝜇m. ∗𝑃 < 0.05 versus control; #𝑃 < 0.05 versus OVA; †𝑃 < 0.05 versus
OVA+Fibroblasts.
5-fold higher than that in controls. However, the proliferation
index was reduced by 71% in epithelium and by 54% in
smoothmuscle layer after c-kit+ cells administration (Figures
3(a)–3(f)). The intense mucus metaplasia observed in OVA
mice was significantly reduced by c-kit+ cells (Figures 3(g)–
3(i)). These results document that c-kit+ cells are able to
attenuate the hyperplastic phase of both bronchial epithelium
and smooth muscle mass, thus reducing airway remodeling.
3.4. Inflammation and Immunomodulation. The increase in
peribronchial infiltration of the inflammatory cells was
evident in the OVA group. However, c-kit+ cells determined
a significant reduction in the extent of inflammatory infiltra-
tion (Figures 4(a)–4(c)). Additionally, the increased number
of mast cells observed in OVA animals became markedly
lowered after cell administration (Figures 4(d)–4(f)). The
analysis of BAL indicated an ongoing inflammation in OVA
mice, given the increase in the total cell number and in
the proportion of lymphocytes, polymorphonucleated cells,
and eosinophils. On the contrary, total and differential cell
counts evidenced a less prominent grade of inflammation
in cell-treated animals (Figure 4(g)). Interestingly, the















































Figure 3: c-kit+ cells positively interfere with the remodeling of asthmatic airways. (a–c) Proliferating (Ki67, green, arrows) epithelial cells
(pan-cytokeratin, CK, red) in vehicle- (a) and c-kit+ cell-treated (b) animals. (c) The fraction of Ki67+ epithelial cells. (d-e) Cycling (Ki67,
green, arrows) SMCs (𝛼-SMA, red) in the airway wall of vehicle- (d) and c-kit+ cell-treated (e) mice. (f) The fraction of Ki67+ SMCs. (g-
h) Mucin-positive goblet cells (green, arrows) in epithelium of vehicle- (g) and c-kit+ cell-treated (h) asthmatic mice. (i) The percentage of
epithelial cells expressing mucin. Data in control, OVA, and OVA+cCs mice are the mean ± SD. Scale bars, (a, b, d, e) 20 𝜇m and (g, h) 10𝜇m.
∗
𝑃 < 0.05 versus control; #𝑃 < 0.05 versus OVA. SMCs: smooth muscle cells; 𝛼-SMA: 𝛼-smooth muscle actin.
augmented fraction of macrophages, reported also with
MSCs [35], suggests the involvement of macrophage acti-
vation in the anti-inflammatory response. Moreover, BAL
from OVA mice showed elevated concentrations of Th2
proinflammatory cytokines (i.e., IL-4, IL-5, and IL-13) while
the levels of IL-10were unchanged. c-kit+ cells administration
determined a reduction in the levels ofTh2 proinflammatory
cytokines and an increase of IL-10 (Figure 4(h)). Since
macrophages play critical role in inflammatory modulation,
their recruitment and polarization have been determined.
The instillation of c-kit+ cells did not affect the total number
of tissue macrophages (marked by pan-marker F4/F80) in
the OVA-treated lungs (not shown). However, in cell-treated
animals, the induction of arginase-1+ M2-like macrophages
activation marker was more prominent, while iNOS+ M1
phenotype was less represented (Figures 4(i)–4(l)) suggesting
preferential polarization into IL-10-producing M2-like cells.
These data indicate that the intratracheal administration
of c-kit+ cells can be responsible for the control of the local
inflammatory process.
In the search for potential mechanisms responsible for
positive effects of c-kit+ cells on the inflammation, isolated
c-kit+ cells were stimulated in vitro with IFN𝛾 and TNF𝛼.
Real-time PCR showed the presence of IL-10 transcript in
resting c-kit+ cells, but no difference was revealed after proin-
flammatory stimulation (Figure 5(a)). Interestingly, when
stimulated, c-kit+ cells showed increased levels of mRNA for
IDO and TGF𝛽 (Figures 5(b) and 5(c)). TGF𝛽-dependent
pathways are essential for IDO regulatory responses [36], and
IDO-producing cells can promote death of lymphocytes by
modifying the local microenvironment [37]. In this regard,
apoptotic rate within inflammatory infiltrates was measured
and became more than 2-fold higher in cell-treated animals
(Figures 5(d)–5(f)). The presence of GFP+ cells in the prox-
imity of the apoptotic inflammatory cells suggests that c-kit+
cells may downregulate, in a paracrine manner, the extent of
the inflammatory infiltrate.
4. Discussion
Asthma is a common chronic disorder of the airways char-
acterized by predominant eosinophilic inflammatory pattern
associated with the whole spectrum of asthma severity, from


















































































































Figure 4: c-kit+ cells interfere with lung inflammation. (a–c) With respect to controls (a), massive accumulation of inflammatory cells is
visible in the lungs of OVA animals (b). The infiltration is markedly reduced in c-kit+-treated asthmatic mice (c). (d, e) Mast cells (toluidine
blue, arrows) in the lungs of vehicle- (d) and c-kit+ cell-treated (e) asthmatic mice. (f) The number of mast cells per mm2 of tissue. (g) Total
cell number and differential cell count in the BAL collected from control, OVA, andOVA+cCsmice. (h) Cytokine levels measured in the BAL.
(i–l) Macrophage polarization as revealed by iNOS (green) and arginase-1 (red) immunostainings in OVA and OVA+cCs lungs. Scale bars,
(a–c, i–l) 50𝜇m and (d, e) 20 𝜇m. Data in control, OVA, and OVA+cCs mice are the mean ± SD. ∗𝑃 < 0.05 versus control; #𝑃 < 0.05 versus
OVA. BALF: bronchoalveolar lavage fluid; mac: macrophages; lymph: lymphocytes; PMN: polymorphonuclear leukocytes; eos: eosinophiles;
iNOS: inducible nitric oxide synthase.
IL-10 mRNA
Stimulated c-kit+ cells






























































Figure 5: Immunomodulatory properties of c-kit+ cells. (a–c) mRNA expression of IL-10 (a), IDO (b), and TGF𝛽 (c) measured by RT-PCR
in unstimulated (C, white bars) and stimulated (blue bars) c-kit+± SD. ∘𝑃 < 0.05 versus unstimulated cells. (d, e) Apoptotic inflammatory
cells (TdT, red, arrowheads) within inflammatory infiltrates in the lungs of vehicle- (d) and c-kit+ cell-treated (e) asthmatic mice. GFP+
cells (green) are present in the close proximity of apoptotic inflammatory cells in c-kit+ cell-treated asthmatic mouse. (f) Apoptotic index of
inflammatory cells in OVA and OVA+cCs animals. #𝑃 < 0.05 versus OVAmice. Scale bars, (d, e) 20 𝜇m. IDO: indoleamine 2,3-dioxygenase;
TGF𝛽: transforming growth factor 𝛽; TdT: terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling.
mild-to-moderate to severe uncontrolled disease [38, 39].
Its pathophysiology involves intermittent airway obstruc-
tion, bronchial hyperreactivity, chronic eosinophilic airway
inflammation, goblet cell hyperplasia, and airway structural
changes in response to a chronicTh2 immune response [40].
Allergens and some diseases have been implicated in the
exacerbation of asthma in both animal models and humans
[41–43].
Increasing reports have indicated that, among several
lung resident stem cell types, c-kit+ cells are important
for pulmonary homeostasis and repair [16–19, 23, 44], but,
to date, their capacity to regulate inflammation has never
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been studied. In the present work, mouse c-kit+ cells were
identified within the normal mouse lung and located mostly
throughout the lung parenchyma and occasionally in the
epithelial layer. In order to observe their behavior in an
experimental model of lung disease, we performed an exoge-
nous cell delivery. Considering the small number present in
a mouse lung, cells were administered intratracheally after
isolation and in vitro expansion. The intratracheal route for
cell delivery used in our study is a methodology that has
several advantages. This type of local administration, rarely
carried out, provides benefits that cannot be extended to a
systemic infusion, such as the reduction of cells number to
be infused and the low risk to engraft other organs.
In our model, the proliferation rate of the epithelium,
the fraction of cycling SMCs, and activation of goblet cells
were significantly higher in the OVA group.This is consistent
with the notion that bronchial epithelial hyperplasia, smooth
muscle layer thickening, and increased number of mucus-
producing cells are key components of airway remodeling
occurring in allergic asthma [2, 45]. Interestingly, mice that
received c-kit+ cells exhibited lowered proliferation index of
both bronchial epithelium and airway SMCs together with
the decrease in the number of goblet cells. Importantly, the
positive effects on the remodeling were coupled with the
improved functional properties of the airways, manifested as
reduced hyperreactivity to ACh. These findings demonstrate
that c-kit+ cells, when placed in this specific pathological
inflammatory condition, can interfere with the cellular aspect
of airway remodeling that contributes to the evolution of
the disease. In our experimental setting, administration of
lung fibroblast did not improve AHR. This indicates that the
modulation of lung function cannot be solely ascribed to
the instillation of a “biomass” into the tissue but represents
a cell type specific phenomenon. Our data do not exclude
the possibility that other lung stem/progenitor cells may
be involved in the response to injury. Understanding the
potential functional relationship between different cell popu-
lations in the diseased lung remains an open and challenging
question.
The attenuation of the immune and inflammatory pro-
cesses can significantly affect bronchial function and home-
ostasis. Indeed, MSCs have been shown to be effective mostly
because of their anti-inflammatory properties while their
capacity to differentiate into epithelial cells remains to be
clarified [20, 46, 47]. Similarly, in our study the inflammatory
processes, typical of this OVA-induced model of experi-
mental AHR, were significantly influenced by exogenously
administered c-kit+ cells. The observed decrease in the num-
ber of inflammatory cells in the BAL and the reduced infiltra-
tion of lung tissue suggested the possible immunomodulatory
properties of tested cell type. The beneficial effects were
associated with a marked reduction of proinflammatory
cytokines IL-4, IL-5, and IL-13 in BAL. In contrast, IL-10, a
potent inhibitor of several proinflammatory cytokines [48–
50], was significantly increased. c-kit+ cells were able to
produce IL-10 in vitro but there was no difference in the IL-
10 transcript after exposure to canonical proinflammatory
stimuli. This indicates that the increase in IL-10 in BAL of
cell-injected animals was probably due to the capacity of
c-kit+ cells to stimulate other cells to secrete this pleiotropic
immunosuppressive cytokine [51, 52]. In this regard, the
involvement of macrophages that represent a potent source
of IL-10 was considered. Activated macrophages regulate
bronchial inflammation and AHR in asthma. Whereas the
classically activated macrophages (M1 subtype) respond to
inflammatory stimuli producing high levels of proinflam-
matory cytokines, M2-like macrophages secrete a range of
anti-inflammatory factors, such as IL-10 [53–55]. Our data
demonstrated that administration of c-kit+ cells determined
a polarization toward M2-like subtype, suggesting that regu-
latory macrophages, among other cell classes able to produce
and release IL-10,may be in part responsible for the inhibition
of inflammation, thus mediating the positive effects of c-kit+
cells on AHR and eosinophilic accumulation.
Furthermore, IDO and TGF𝛽 mRNAs were markedly
increased in stimulated cells. IDO modulates the immune
response by inducing a rapid depletion of the amino acid
tryptophan and by leading to the formation of proapoptotic
metabolites [37], whereas TGF𝛽 is able to downregulate
the allergic response [56]. Moreover, IDO, TGF𝛽, and
prostaglandin E2 secreted by adipose-derived MSCs amelio-
rate airway inflammation and improve lung function [57].
The observations that GFP-labeled c-kit+ cells were present
within inflammatory infiltrates and that the apoptosis of
inflammatory cells was higher in cell-treated animals support
the hypothesis of local immunoregulation as a possible
regulatory mechanism.
Several factors have been proposed to mediate immuno-
suppressive effect, including IDO, TGF𝛽, prostaglandin E2,
hepatocyte growth factor, nitric oxide, and IL-10. A number
of specific immune cell populations are involved and their
recruitment and direct or indirect capacity to secrete biologi-
cal factorsmay explain paracrine immunosuppressive activity
observed in experimental studies with stem cells or trophic
molecules. Myeloid-derived suppressor cells (MDSCs) are
innate immune cells characterized by their potential to
control T cell responses and inhibit inflammation. It has
been reported that MDSC accumulation positively correlates
with the increase of IL-10 by both direct production and
an interaction between MDSCs and macrophages [58, 59].
There is also evidence for distinct roles of conventional and
plasmacytoid dendritic cells in regulating T cell-mediated
adaptive immunity in the lung [60]. Conventional dendritic
cells promote Th2 sensitization [61], whereas plasmacy-
toid dendritic cells exert anti-inflammatory effects for their
capacity to release IDO thus inhibiting T cell responses
[62, 63]. To date, no study addressed the in vivo influence
of c-kit+ cells on immune system, and the only relevant
information can be extrapolated from paracrine effects of
MSCs. MSCs regulate, via TGF𝛽 and/or IDO, the function
of CD4+ CD25+ FoxP3+ regulatory T cells and NK cells
and, through prostaglandin E2, the maturation/activation of
dendritic cells [64, 65]. However, in the search ofmechanisms
by which MSCs mediate immunomodulation, cell-to-cell
contact should be considered as well, as demonstrated by
in vitro studies showing a direct participation of MSCs in
the regulation of immune cell behavior [66, 67]. We did not
examine the effect of c-kit+ cells on different populations of
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lymphocytes; the data on macrophage polarization suggest
that c-kit+ cells can promote accumulation/activation of cells
releasing immunosuppressive cytokines. Our data regarding
the improved airway function and the wide range of actions
that c-kit+ cells share with MSCs make the possible interac-
tion with a variety of immune cells more than reasonable.
Further investigations and ad hoc experiments are needed to
clarify the mechanisms involved in the modulation of anti-
inflammatory response driven by c-kit+ cells.
5. Conclusion
In the present study we report that c-kit+ cells, isolated
from adult lung, improve lung function through the restraint
of inflammatory processes. The secretion of multiple sol-
uble mediators, switching off a proinflammatory state and
favoring an anti-inflammatory condition, can explain the
immunosuppressive effect of c-kit+ cells in vivo, which
resembles the known action attributed to MSCs. The capa-
bility to modify the inflammatory environment, possibly in a
paracrine and cell-to-cell contact manner, can be considered
as a new feature of c-kit+ cells, in addition to their participa-
tion in tissue homeostasis [16–18].
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